Evolving Approaches for the Management of Waldenström’s Macroglobulinemia

Learning Objectives

After completing this program, participants should be able to:

• Outline the criteria required to accurately diagnose patients with WM and identify those most likely to benefit from treatment
• Describe the approved treatment paradigms for patients with WM
• Discuss the mechanisms of action of novel investigational agents and review the clinical outcomes of these agents in patients with WM

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Faculty